KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual ObligationsCost Of SalesEmployee StatisticsGross Margin %Gross Margin Annual %Gross ProfitGross Profit AnnualIncome Before Income TaxesNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Operating Expense SegregationOpex As A % Of RevenueProperty, Plant & Equipment, Net BreakdownR&D As A %R&D SegregationRevenueRevenue By Customer TypeRevenue By Customer Type %Revenue By ProductRevenue By Product %Revenue By Product AnnualRevenue By Product Annual %Revenue By SegmentRevenue By Segment %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Revenue (2016 - 2025)

Historic Revenue for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $278.6 million.

  • Acadia Pharmaceuticals' Revenue rose 1127.47% to $278.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 1268.59%. This contributed to the annual value of $957.8 million for FY2024, which is 3184.86% up from last year.
  • As of Q3 2025, Acadia Pharmaceuticals' Revenue stood at $278.6 million, which was up 1127.47% from $264.6 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year Revenue high stood at $278.6 million for Q3 2025, and its period low was $106.6 million during Q1 2021.
  • Over the past 5 years, Acadia Pharmaceuticals' median Revenue value was $165.2 million (recorded in 2023), while the average stood at $182.8 million.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Revenue plummeted by 68.23% in 2022 and then skyrocketed by 7375.28% in 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' Revenue (Quarter) stood at $130.8 million in 2021, then grew by 4.38% to $136.5 million in 2022, then surged by 69.27% to $231.0 million in 2023, then rose by 12.36% to $259.6 million in 2024, then increased by 7.33% to $278.6 million in 2025.
  • Its last three reported values are $278.6 million in Q3 2025, $264.6 million for Q2 2025, and $244.3 million during Q1 2025.